NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration with TargetGene

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced a strategic collaboration with TargetGene Biotechnologies Ltd. to advance next-generation gene-edited cell therapies. The collaboration will leverage Kadimastem’s cell therapy platforms, including AstroRx® for ALS and IsletRx for diabetes, combined with TargetGene’s precision gene-editing technology. The partnership aims to develop and optimize gene-edited cell therapy products to enhance therapeutic performance, stability, and safety. The collaboration is expected to continue under the combined company, NewCelX, upon the completion of the anticipated merger between NLS and Kadimastem. This partnership represents a significant step in advancing curative, scalable, and commercially viable cell-based treatments for severe diseases.